Ermias Tilahun, MPH, PhD., brings over 15 years of experience in epidemiology, clinical research, and public health, academia, clinical healthcare, the pharmaceutical industry, non-profit organizations, and regulatory settings. Currently serving as an Epidemiologist at the FDA, he specializes in research methodology, clinical research management, data analysis, and public health education.
With a Ph.D. in Pharmacoepidemiology, a Master’s in Public Health (MPH), a B.Sc. in Physician Assistant Studies, and a Diploma in Crisis Management and Post-Conflict Rehabilitation, Dr. Ermias combines a strong academic foundation with hands-on expertise in drug safety, surveillance, and health outcomes research.
At the FDA’s Office of Pharmacovigilance and Epidemiology (OPE), he supported drug safety evaluations, assessing efficacy, nonmedical use, and reproductive health outcomes. Prior to this, as a Scientist at Pfizer, Dr. Ermias developed a manuscript and analysis plan for a claims-based study using National Inpatient Survey (NIS) data and managed a global bacterial serotype distribution database for Invasive Pneumococcal Disease (IPD) surveillance. His earlier research at Howard University focused on survey design and data analysis to evaluate Medicare beneficiaries’ awareness of pharmacist-provided Medication Therapy Management (PP-MTM) services.
Beyond research, Dr. Ermias is actively involved in mentorship, education, and professional leadership, having served as a educator, Pharmacovigilance adviser, and association leader. With expertise in curriculum development, quantitative and qualitative research, survey design, literature review, and biostatistical analysis, he contributes valuable insights to the field of clinical research, pharmacoepidemiology, pharmacovigilance, and public health.
